Skip to main content
OpenTrials
Completed

NCT Number: NCT00903877

Study of T3 for the Treatment of Fibromyalgia

Determine if T3 - the active form of thyroid hormone - is beneficial in fibromyalgia. Determine the feasibility and promise of an appropriately powered future prospective randomized controlled study of using T3 (the active form of thyroid hormone) for the treatment of fibromyalgia. We specifically aim to assess the feasibility, cost, obstacles and promise of conducting a prospective controlled study in the future.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Fibromyalgia Muscular Diseases Musculoskeletal Diseases Nervous System Diseases Neuromuscular Diseases Rheumatic Diseases

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Stanford University School of Medicine

Stanford, California, 94305, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-50
  • Meet american college of rheumatology criteria for fibromyalgia
  • at baseline report an average pain of 4 or more on a brief Pain Inventory.
  • can climb 2 flights of stairs without shortness of breath.

Exclusion criteria

  • new medication change in the last 2 months
  • any cardiac disease at all
  • known thyroid disease before or after thyroid screening bloodwork
  • unstable medical or psychiatric disease.
  • Known inflammatory or rheumatic disease other than fibromyalgia
  • substance abuse in the last year
  • suicidality or depression as indicated by a Beck Depression Inventory of 30 or above
  • concomitant herbal medications
  • multiple severe medication allergies
  • the assessment of the research team that inclusion of the subject could in some way compromise the safety and validity of the study.
  • diabetes
  • smoking
  • Known uncontrolled hypertension
  • known uncontrolled hypercholesterolemia

Treatment and study plan

T3

Drug

Patients receive T3 in a dose of 25mcg and 50mcg

Primary outcomes

  1. Visual Analogue Scale of Pain Intensity

    Time frame: 12 weeks

    Patients rated their pain at baseline, placebo, T3 at 25 mcg, and T3 at 50 mcg. The scale ranged from 0 (no pain) to 10 (pain as bad as it can be).

Sponsors and collaborators

Lead sponsor

Stanford University

Other

Registry information

Official study title

T3 for Fibromyalgia: a Pilot Double-blind Non-randomized Clinical Trial

Important dates

Study start
2009
Primary completion
2011
Study completion
2011
First posted
May 19, 2009
Registry last updated
Jul 14, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.